Medication info
Olmesartan 5/20 milligrams

Olmesartan 5/20 milligrams

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›6.944mg / 1 tabletOlmesartan Medoxomil›20mg / 1 tablet
Manufacturer / importer
Withus Pharmaceutical Co., Ltd.
Appearance
White round film-coated tablets
Packaging
30 tablets/box [10 tablets/PTP x 3]
Approval status
Active

MFDS item code 202001260 · Approved 2020.02.21 · Insurance code 660703330

Summary

Main use
Treatment of essential hypertension
Who takes it
Adults · Children
Adult dose
Administer 1 tablet of this medicine once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. Since the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of at least 2 weeks, taking the patient’s blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ◦ Patients with renal impairment : This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal failure (creatine clearance 20-60mL/min) is 20 milligrams once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal failure. ◦ Patients with reduced effective intravascular volume : In patients who may have reduced effective intravascular volume (Intravascular volume depletion) (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ◦ Patients with hepatic impairment : Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2, ‘Patients who must not receive this medicine,’ under Precautions for Use.) ◦ Older adults : In general, initiate treatment at a low dose. When adjusting the dose, take the patient’s renal or cardiac function and comorbidities into consideration. Blood pressure should be monitored closely and more frequently in older adults.
Child dose
Safety and efficacy have not been established in pediatric patients younger than 18 years.

Ingredients

Manufacturer
Withus Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension

  • Essential hypertension
View approved original text

Amlodipine or olmesartan medoxomil is used as monotherapy in patients with essential hypertension when blood pressure is poorly controlled. These drugs dilate blood vessels to lower blood pressure, thereby reducing cardiovascular strain and the risk of complications. They effectively control blood pressure through different mechanisms of action, aiding in the management of patients' blood pressure. Thus, they play an important role in improving the treatment of essential hypertension.

How to take

Adult dose

Administer 1 tablet of this medicine once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. Since the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of at least 2 weeks, taking the patient’s blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ◦ Patients with renal impairment : This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal failure (creatine clearance 20-60mL/min) is 20 milligrams once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal failure. ◦ Patients with reduced effective intravascular volume : In patients who may have reduced effective intravascular volume (Intravascular volume depletion) (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ◦ Patients with hepatic impairment : Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2, ‘Patients who must not receive this medicine,’ under Precautions for Use.) ◦ Older adults : In general, initiate treatment at a low dose. When adjusting the dose, take the patient’s renal or cardiac function and comorbidities into consideration. Blood pressure should be monitored closely and more frequently in older adults.

Child dose

Safety and efficacy have not been established in pediatric patients younger than 18 years.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters; therefore, it should be discontinued immediately upon confirmation of pregnancy. This medication should not be taken by individuals with allergies to any of its components, those who are pregnant or breastfeeding, those with severely impaired liver or kidney function, or those with severe heart valve diseases. Patients who are deficient in fluid or salt or have significantly low blood pressure should be carefully monitored when starting this medication, and appropriate treatment is needed if hypotension occurs. Patients with heart valve diseases or obstructive coronary artery diseases should be particularly cautious as blood pressure may suddenly drop due to rapid vasodilation. Patients with heart failure should be careful when using this medication, and patients with impaired kidney function should closely monitor their kidney function while taking this medication. Patients with impaired liver function should also be cautious when taking this medication. Various side effects such as dizziness, headache, hypotension, swelling, dyspepsia, etc., may occur during the use of this medication, and any abnormal symptoms should be discussed with a doctor immediately. This medication may increase blood potassium levels; therefore, patients at risk of hyperkalemia should have regular blood tests. There may be drug interactions with this medication, so if you are taking other medications, you must inform your doctor or pharmacist. It is a principle not to use this medication during pregnancy, and if it must be used, the fetal status should be regularly monitored via ultrasound or other methods. Breastfeeding women are advised to discontinue breastfeeding or stop taking this medication as it can be transmitted through breast milk. The safety and efficacy of this medication have not been established in children under 18 years of age, so it is advisable not to use it in this population. Elderly patients should start at a lower dose considering the potential decline in kidney and liver function, and dosage should be adjusted with caution. In case of overdose, blood pressure may drop excessively, requiring immediate medical attention for appropriate treatment. This medication should be stored in a tightly sealed container to avoid exposure to direct sunlight and moisture, and it is recommended not to transfer it to another container.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • reduced sensation
  • syncope
Show 82 more
  • vertigo
  • palpitations
  • rapid pulse
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • lumbago
  • frequent urination
  • erectile dysfunction
  • peripheral edema
  • edema
  • pitting edema
  • fatigue
  • asthenia
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin
  • decreased hematocrit
  • cholelithiasis
  • female breast neoplasm
  • exacerbation of cerebral infarction
  • gum bleeding
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • rhinorrhea
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • shingles
  • diplopia
  • insomnia
  • asthenia
  • angioedema
  • chronic malabsorption syndrome
  • intestinal vascular edema
  • rhabdomyolysis
  • acute renal failure
  • hair loss
  • itching
  • autoimmune hepatitis
  • angioedema
  • increased serum creatinine
  • urticaria
  • jaundice
  • increased liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • flushing
  • fatigue
  • edema
  • palpitations
  • dizziness
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • gynecomastia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to prevent contact with air or moisture. It is recommended to maintain a storage temperature in the range of 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

White round film-coated tablets

Package unit

30 tablets/box [10 tablets/PTP x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.